Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Other Working Capital Changes (2023 - 2025)

Historic Other Working Capital Changes for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $790000.0.

  • BioLineRx's Other Working Capital Changes rose 12451.89% to $790000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 15193.19%. This contributed to the annual value of -$13.0 million for FY2024, which is 20000.0% down from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Other Working Capital Changes is $790000.0, which was up 12451.89% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Other Working Capital Changes registered a high of $13.5 million during Q4 2023, and its lowest value of -$3.9 million during Q1 2024.
  • Over the past 3 years, BioLineRx's median Other Working Capital Changes value was -$566000.0 (recorded in 2023), while the average stood at $71818.2.
  • In the last 5 years, BioLineRx's Other Working Capital Changes crashed by 314793.39% in 2024 and then soared by 12944.02% in 2025.
  • Over the past 3 years, BioLineRx's Other Working Capital Changes (Quarter) stood at $13.5 million in 2023, then tumbled by 116.68% to -$2.3 million in 2024, then surged by 135.03% to $790000.0 in 2025.
  • Its Other Working Capital Changes stands at $790000.0 for Q3 2025, versus -$1.2 million for Q2 2025 and $1.2 million for Q1 2025.